ReviewMolecular diagnosis & therapy2023
Flotufolastat F 18: Diagnostic First Approval.
Review in Molecular diagnosis & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Detection rate of PSMA PET MRI (18 F-Flotufolastat) at the onset of biochemical recurrence following radical prostatectomy.EJNMMI reports · 2026Article
- Novel PSCA-Targeting Adapter Molecules for Late-Stage RevCAR-T Cell Therapy in Prostate Cancer.International journal of molecular sciences · 2026Article
- Pharmacological Insights on USFDA-approved Novel Drug Therapies in the Year 2023.Current drug discovery technologies · 2026Review
- Evaluation of Bifunctional, PSMA-Targeted Triazamacrocycle-Picolinates Compatible with theJournal of medicinal chemistry · 2025Article
- Theranostics 2.0: Target-driven, artificial intelligence-enabled cancer therapy across tumor types.Diagnostic and interventional imaging · 2025Review
- CAR-T Cell Therapy for Prostate Cancer: Current Advances and Future Perspectives.Biomedicines · 2025Review
- Pharmacological aspects of FDA-approved novel drug therapies against cancer in 2023: a comprehensive review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Enhancing the radionuclide theranostic concept through the radiohybrid approach.RSC medicinal chemistry · 2025Review
- Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.Signal transduction and targeted therapy · 2025Review
- A Personalized Approach for Oligometastatic Prostate Cancer: Current Understanding and Future Directions.Cancers · 2025Review
- FDA-approved drugs featuring macrocycles or medium-sized rings.Archiv der Pharmazie · 2025Review
- Exploring the Potential of Pyridine Carboxylic Acid Isomers to Discover New Enzyme Inhibitors.Drug design, development and therapy · 2025Review
- Current clinical applications of Cerenkov luminescence for intraoperative molecular imaging.European journal of nuclear medicine and molecular imaging · 2024Review
- Review
- The Role of Small Molecules Containing Fluorine Atoms in Medicine and Imaging Applications.Pharmaceuticals (Basel, Switzerland) · 2024Review
- 2023 FDA TIDES (Peptides and Oligonucleotides) Harvest.Pharmaceuticals (Basel, Switzerland) · 2024Review
- "One Method to Label Them All": A Single Fully Automated Protocol for GMP-CompliantCurrent radiopharmaceuticals · 2024Article
- Highlights on Fluorine-containing Drugs Approved by U.S. FDA in 2023.Current topics in medicinal chemistry · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Flotufolastat F 18 (POSLUMA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.